Ah, the IL-23/IL-17 axis is central in driving inflammation, but the gut has its own unique geography. Drugs blocking IL-17 can paradoxically worsen Crohn’s, likely due to disrupting the mucosal barrier, while IL-23 inhibitors show promise in both Crohn’s and ulcerative colitis by targeting a more upstream pathway. This specificity reminds me of my own pension PIN—a small, crucial detail in a larger system that, if misapplied, causes more trouble than ease. Just as I cannot use the same code for every financial need, we cannot assume the same inflammatory pathway behaves identically in different terrains of the gut.
#fitness#health
Jump in to reply — no account needed.